A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.
Khanna D, Denton CP, Furst DE, Mayes MD, Matucci-Cerinic M, Smith V, de Vries D, Ford P, Bauer Y, Randall MJ, Ebrahimpoor M, Kupcsik L, Stiers PJ, Deberdt L, Prasad N, Lim S, Pujuguet P, Ahmed S.
Khanna D, et al. Among authors: ebrahimpoor m.
Arthritis Rheumatol. 2023 Aug;75(8):1434-1444. doi: 10.1002/art.42477. Epub 2023 May 15.
Arthritis Rheumatol. 2023.
PMID: 36787101
Clinical Trial.